Home / Market News / $SMMT
benzinga Corporate Catalyst Impact 65/100 ● positive

Summit Therapeutics Announces Clinical Trial Collaboration With The ECOG-ACRIN Cancer Research Group To Evaluate Ivonescimab In A Phase II/III Study In Biliary Tract Cancer

Oct 21, 2026, 10:07 AM UTC · Primary ticker $SMMT

Summit Therapeutics announced a clinical trial collaboration with ECOG-ACRIN for a Phase II/III study of ivonescimab in biliary tract cancer (BTC). This collaboration signifies a significant step in expanding ivonescimab's development program into a new, difficult-to-treat cancer, potentially broadening its market opportunity.

Summit Therapeutics is collaborating with ECOG-ACRIN for a Phase II/III study (EA2251) of ivonescimab in first-line advanced biliary tract cancer (BTC). This is a significant development for Summit as it expands the potential indications for ivonescimab into an area of high unmet medical need, demonstrating scientific interest from a leading cooperative oncology group. The study will compare ivonescimab plus chemotherapy against current standard-of-care immunotherapy regimens (pembrolizumab or durvalumab plus chemotherapy), with overall survival as the primary endpoint. For traders, this represents a long-term opportunity for Summit if the trial is successful, potentially opening up a new market. Short-term impact is moderate as trial activation is not until Q4 2026, but it validates the drug's potential. Competitors like Merck (pembrolizumab) and AstraZeneca (durvalumab) are indirectly affected as their drugs are used as comparators, but the immediate impact on them is minimal.

$SMMT positive Expanding clinical development for key drug
$MRK neutral Competitor in clinical trial comparison
$AZN neutral Competitor in clinical trial comparison
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.